biote (NASDAQ:BTMD – Get Free Report) and Clover Health Investments (NASDAQ:CLOV – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.
Insider and Institutional Ownership
21.7% of biote shares are owned by institutional investors. Comparatively, 19.8% of Clover Health Investments shares are owned by institutional investors. 32.4% of biote shares are owned by insiders. Comparatively, 23.5% of Clover Health Investments shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings and price targets for biote and Clover Health Investments, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| biote | 1 | 1 | 1 | 1 | 2.50 |
| Clover Health Investments | 1 | 3 | 2 | 0 | 2.17 |
Profitability
This table compares biote and Clover Health Investments’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| biote | 3.19% | -22.33% | 12.10% |
| Clover Health Investments | -0.74% | -4.20% | -2.28% |
Earnings and Valuation
This table compares biote and Clover Health Investments”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| biote | $192.22 million | 0.21 | $27.05 million | $0.11 | 10.18 |
| Clover Health Investments | $1.92 billion | 1.26 | -$85.55 million | ($0.05) | -91.10 |
biote has higher earnings, but lower revenue than Clover Health Investments. Clover Health Investments is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
biote has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Comparatively, Clover Health Investments has a beta of 2.45, indicating that its share price is 145% more volatile than the S&P 500.
Summary
biote beats Clover Health Investments on 10 of the 15 factors compared between the two stocks.
About biote
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
About Clover Health Investments
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.
Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.
